Sanofi Consumer Healthcare India Ltd

Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India ' a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, 'We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.' SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofi's global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra', DePURA', Avil', and Combiflam'. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday. Powered by Capital Market - Live

Net profit of Sanofi Consumer Healthcare India declined 20.26% to Rs 50.00 crore in the quarter ended March 2025 as against Rs 62.70 crore during the previous quarter ended March 2024. Sales declined 22.11% to Rs 172.60 crore in the quarter ended March 2025 as against Rs 221.60 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales172.60221.60 -22 OPM %37.0836.91 - PBDT68.8084.80 -19 PBT66.8083.90 -20 NP50.0062.70 -20 Powered by Capital Market - Live

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live

Sanofi Consumer Healthcare India has revised the record date from 28 April 2025 to 17 April 2025 for final dividend of Rs 55 per equity share of face value of Rs 10 each for the year ended 31 December 2024. Powered by Capital Market - Live

According to an exchange filing, Mistry has decided to resign to explore new opportunities outside the organization. In addition, Rupendra Sachdev, the head of commercial operations and a senior management personnel, has also decided to step down from his current role. His resignation will be effective from the end of business hours on 30 April 2025, marking his last working day with the company. Sachdev is leaving to pursue his entrepreneurial aspirations. Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce. Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24. The counter shed 0.85% to Rs 4,740.15 on the BSE. Powered by Capital Market - Live

Sanofi Consumer Healthcare India announced that the 2nd Annual General Meeting(AGM) of the company will be held on 5 May 2025.Powered by Capital Market - Live

Total operating expenditure rose by 13.8% YoY to Rs 111.50 crore in Q3 FY25, due to higher finished good purchases (up 27.8% YoY) and higher other expenses (up 31.7% YoY). Profit before tax in Q3 FY25 stood at Rs 62.80 crore, up by 2.6% from Rs 61.20 crore in Q3 FY24. Tax outgo for the period under review was Rs 17.60 crore, up by 4.1% YoY. Sanofi Consumer Healthcare India is engaged in the consumer healthcare (CHC) business. It has a presence in allergy, physical wellness, and pain care segments through brands like Allegra, Combiflam, Avil, and DePURA. It also has brands like Festal, Baralgan, and Novalgin NU in its portfolio. The company's distribution capabilities cover channels such as distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains and e-commerce. The scrip slipped 1.18% to currently trade at Rs 4709.30 on the BSE. Powered by Capital Market - Live

Sanofi Consumer Healthcare India announced that the Board of Directors of the Company at its meeting held on , inter alia, have recommended the final dividend of Rs 55 per equity Share (i.e. 550%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Sanofi Consumer Healthcare India declined 1.56% to Rs 44.30 crore in the quarter ended December 2024 as against Rs 45.00 crore during the previous quarter ended December 2023. Sales rose 6.75% to Rs 170.70 crore in the quarter ended December 2024 as against Rs 159.90 crore during the previous quarter ended December 2023. For the full year,net profit rose 9.83% to Rs 181.00 crore in the year ended December 2024 as against Rs 164.80 crore during the previous year ended December 2023. Sales rose 37.89% to Rs 724.50 crore in the year ended December 2024 as against Rs 525.40 crore during the previous year ended December 2023. ParticularsQuarter EndedYear EndedDec. 2024Dec. 2023% Var.Dec. 2024Dec. 2023% Var. Sales170.70159.90 7 724.50525.40 38 OPM %36.3839.46 -37.3541.66 - PBDT66.7063.90 4 279.70223.00 25 PBT65.7062.40 5 275.20221.00 25 NP44.3045.00 -2 181.00164.80 10 Powered by Capital Market - Live

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 20 February 2025.Powered by Capital Market - Live